Building Engagement Using Financial Incentives Trial - Colorectal Cancer Screening

Colorectal Cancer Clinical Trial

— BENEFIT-C  

Official title:

Building Engagement Using Financial Incentives Trial - Colorectal Cancer Screening

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT06124131
• Other study ID #: 2020-1600-BENC
• Secondary ID: OT2HL158287
• Status: Completed
• Phase: N/A
• Start date: November 11, 2023
• Est. completion date: March 25, 2024

Study information

• Verified date: April 2024
• Source: Tulane University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The goal of this pilot clinical trial is to determine feasibility and explore whether financial incentives paid to primary care patients for completing colorectal cancer screening increase completion of colorectal cancer screening. The main questions it aims to answer are:

• Do patient financial incentives for completing colorectal cancer screening increase screening completion?

• Does a patient financial incentive for colorectal cancer screening offered alongside patient financial incentives for COVID-19 and flu shots increase completion of those shots?

Participants who are due for colorectal cancer screening will receive telephone outreach from primary care staff who will offer a stool-based colorectal cancer screening. Participants will be randomly assigned to either Group 1 or Group 2. Group 1 participants will be offered financial incentives for completing COVID-19 and flu shots within 2 months of enrollment. Group 2 participants will be offered financial incentives for completing a COVID-19 shot, a flu shot, and colorectal cancer screening within 2 months of enrollment.

Researchers will compare to see if completion of a COVID-19 shot, a flu shot, and colorectal cancer screening is different between the two groups.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 50
• Est. completion date: March 25, 2024
• Est. primary completion date: March 25, 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 45 Years to 75 Years

Eligibility

Inclusion Criteria:

• Age 45 to 75

• Receive care at participating primary care clinic

• Due for colorectal cancer screening

• Ability to understand and speak English

Exclusion Criteria:

• Currently participating in another clinical trial or research study on colorectal cancer screening

• Unable or unwilling to give informed consent

Related Conditions & MeSH terms

• Colorectal Cancer
• Colorectal Neoplasms
• COVID-19
• Health Behavior
• Influenza
• Vaccine Hesitancy

Intervention

Behavioral:
• Financial incentive for colorectal cancer screening
$50 incentive paid to participant for completion of colorectal cancer screening within 2 months of enrollment
• Financial incentive for flu shot
$50 incentive paid to participant for completion of flu shot within 2 months of enrollment
• Financial incentive for COVID-19 shot
$50 incentive paid to participant for completion of COVID-19 shot within 2 months of enrollment

Locations

Country	Name	City	State
United States	Tulane University School of Medicine	New Orleans	Louisiana

Sponsors (2)

Lead Sponsor	Collaborator
Tulane University	National Heart, Lung, and Blood Institute (NHLBI)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Number of patients approached for recruitment	Number of patients with reachable phone numbers	Three months
Other	Number of patients assessed for eligibility	Number of patients who begin eligibility screener	Three months
Other	Number of patients randomized	Number of patients who consent and are randomized	Three months
Other	Number of patients who receive intended treatment	Number of patients who complete outreach call	Three months
Primary	Difference in proportion of participants completing colorectal cancer screening between study arms	Completion of colonoscopy, sigmoidoscopy, CT colonography, or stool-based colorectal cancer screening test as documented in electronic health record within two months of study enrollment	Two months
Secondary	Difference in proportion of participants completing COVID-19 shot between study arms	Completion of COVID-19 shot as documented in electronic health record within two months of study enrollment	Two months
Secondary	Difference in proportion of participants completing flu shot between study arms	Completion of flu shot as documented in electronic health record within two months of study enrollment	Two months
Secondary	Difference in proportion of participants completing at least one of the following services between study arms: colorectal cancer screening, COVID-19 shot, flu shot	Completion of colorectal cancer screening (colonoscopy, sigmoidoscopy, CT colonography, or stool-based colorectal cancer screening test), COVID-19 shot, *OR* flu shot as documented in electronic health record within two months of study enrollment	Two months
Secondary	Difference in proportion of participants completing all three services between study arms: colorectal cancer screening, COVID-19 shot, flu shot	Completion of colorectal cancer screening (colonoscopy, sigmoidoscopy, CT colonography, or stool-based colorectal cancer screening test), COVID-19 shot, *AND* flu shot as documented in electronic health record within two months of study enrollment	Two months